BACKGROUND: @entity4238 ( @entity19392 ), a preoccupation with an imagined or slight defect in appearance, is a relatively common and @entity73 . While available data suggest that @entity750 reuptake inhibitors are effective for @entity19392 , investigation of this disorder's response to pharmacotherapy is limited, and there are no published reports on the efficacy of the selective @entity750 reuptake inhibitor @entity837 . In addition, there are no published reports on change in quality of life and multiple domains of psychosocial functioning with pharmacologic treatment for @entity1 with @entity19392 . METHOD: Fifteen subjects with DSM-IV @entity19392 or its delusional variant were prospectively treated in a 12-week open-label trial of @entity837 . Subjects were assessed at regular intervals with the Yale-Brown Obsessive Compulsive Scale Modified for @entity19392 ( @entity19392 ; the primary outcome measure), the Clinical Global Impressions scale (CGI), the Brown Assessment of Beliefs Scale, measures of quality of life and multiple domains of psychosocial functioning, and other scales. Data were collected from Dec. 28, 1999, to March 1, 2001. RESULTS: On the @entity19392 , scores decreased from a mean +/- SD of 30.7 +/- 4.9 at baseline to 15.3 +/- 10.6 at endpoint (p <.001), and 73.3% (N = 11) of subjects were responders. On the CGI, 40.0% of @entity1 (N = 6) were very much improved, and 26.7% (N = 4) were much improved. Psychosocial functioning and mental health-related quality of life also significantly (p <.05) improved. The mean dose of @entity837 was 51.3 +/- 16.9 mg/day, and the mean time to response was 4.6 +/- 2.6 weeks. @entity837 was generally well tolerated. CONCLUSION: @entity837 appears safe and effective for @entity19392 . Psychosocial functioning and quality of life also significantly improved with @entity837 .

An open-label study of @entity837 in body XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impairing disorder'] @entity837 :: ('MESH:D015283', 'Chemical') :: ['citalopram', 'Citalopram'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity4238 :: ('MESH:D057215', 'Disease') :: ['Body dysmorphic disorder'] @entity19392 :: ('MESH:C562420', 'Disease') :: ['BDD', 'BDD-YBOCS']
@entity4238 :: (MESH:D057215,Disease) :: ['dysmorphic disorder']
